Xanthine oxidase inhibition for hyperuricemic heart failure patients design and rationale of the EXACT-HF study

Circulation: Heart Failure

Volumn 6, Issue 4, 2013, Pages 862-868

  Givertz, Michael M ^a   Mann, Douglas L ^b   Lee, Kerry L ^c   Ibarra, Jenny C ^c   Velazquez, Eric J ^c   Hernandez, Adrian F ^c   Mascette, Alice M ^d   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Allopurinol; Clinical trial; Heart failure; Xanthine oxidase

Indexed keywords

ALLOPURINOL; DIURETIC AGENT; OXIPURINOL; PLACEBO; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SCAVENGER;

ABSENCE OF SIDE EFFECTS; AGRANULOCYTOSIS; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC KIDNEY DISEASE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; EXPERIMENTAL MODEL; GOUT; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERURICEMIA; HYPERURICEMIC HEART FAILURE; INTRAUTERINE GROWTH RETARDATION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER TOXICITY; MORTALITY; NAUSEA; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RASH; RISK; SARCOPENIA; SLEEP DISORDERED BREATHING; STABLE ANGINA PECTORIS; STEVENS JOHNSON SYNDROME; VASCULITIS; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR ENDOTHELIUM;

ALLOPURINOL; CLINICAL TRIAL; HEART FAILURE; XANTHINE OXIDASE;

ALLOPURINOL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FREE RADICAL SCAVENGERS; HEART FAILURE; HUMANS; HYPERURICEMIA; OXIDATIVE STRESS; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REACTIVE OXYGEN SPECIES; RESEARCH DESIGN; XANTHINE OXIDASE;

EID: 84884708394     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000394     Document Type: Article

References (45)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-e479.
3. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 1998;97:1536-1539.
4. Karantalis V, Schulman IH, Hare JM. Nitroso-redox imbalance affects cardiac structure and function. J Am Coll Cardiol. 2013;61:933-935.
5. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med. 2004;351:2112-2114.
6. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997.
7. Kittleson MM, St John ME, Bead V, Champion HC, Kasper EK, Russell SD, Wittstein IS, Hare JM. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart. 2007;93:365-367.
8. Nash HL, Fitz AE, Wilson WR, Kirkendall WM, Kioschos JM. Cardiorenal hemodynamic effects of ethacrynic acid. Am Heart J. 1966;71:153-165.
9. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W. Uric acidlowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3:73-81.
10. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18:858-865.
11. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433.
12. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH, Goldberg LR, Jessup M, Cappola TP. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012;5:183-190.
13. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358-1364.
14. Málek F, Ošťádal P, Pařenica J, Jarkovský J, Vítovec J, Widimský P, Linhart A, Fedorco M, Coufal Z, Miklík R, Kruger A, Vondraková D, Špinar J. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure-results of the Acute HEart FAilure Database registry. J Crit Care. 2012;27:737.e11-737.e24.
15. Gotsman I, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail. 2012;18:694-701.
16. Murphy RM, Dutka TL, Lamb GD. Hydroxyl radical and glutathione interactions alter calcium sensitivity and maximum force of the contractile apparatus in rat skeletal muscle fibres. J Physiol. 2008;586:2203-2216.
17. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, Kass DA, Marbán E, Hare JM. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res. 1999;85:437-445.
18. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marbán E, Hare JM. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411.
19. Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol. 2012;59:802-808.
20. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221-226.
21. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508-2516.
22. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Pérez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail. 2006;12:491-498.
23. Erdogan D, Tayyar S, Uysal BA, Icli A, Karabacak M, Ozaydin M, Dogan A. Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2012;28:721-727.
24. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51:2301-2309.
25. Freudenberger RS, Schwarz RP, Jr, Brown J, Moore A, Mann D, Givertz MM, Colucci WS, Hare JM. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. Expert Opin Investig Drugs. 2004;13:1509-1516.
26. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260-266.
27. Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation. 2013;127:500-7; discussion 508.
28. Zyloprim (allopurinol) tablet. Daily Med Web site. http://dailymed.nlm. nih.gov/dailymed/drugInfo.cfm?id=13564. Accessed March 30, 2013.
29. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46:623-644.
30. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-2432.
31. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135-140.
32. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20:391-395.
33. Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Struthers AD. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol. 2011;58:820-828.
34. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, Lang CC, George J, Struthers AD. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61:926-932.
35. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J. 2008;49:384-387.
36. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7:176-182.
37. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35: 1245-1255.
38. Larsen AI, Aarsland T, Kristiansen M, Haugland A, Dickstein K. Assessing the effect of exercise training in men with heart failure; comparison of maximal, submaximal and endurance exercise protocols. Eur Heart J. 2001;22:684-692.
39. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The sixminute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest. 1996;110:325-332.
40. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. 1993;270:1702-1707.
41. Chapman DG, Nam JM. Asymptotic power of chi square tests for linear trends in proportions. Biometrics. 1968;24:315-327.
42. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of highdose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375:2161-2167.
43. Stone PH. Allopurinol a new anti-ischemic role for an old drug. J Am Coll Cardiol. 2011;58:829-830.
44. http://clinicaltrials.gov/ct2/results?term=allopurinol&recr=Open. Accessed March 30, 2013.
45. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-1904.